Nanocarriers for resveratrol delivery: Impact on stability and solubility concerns

Santos, Ana Cláudia; Pereira, Irina; Pereira-Silva, Miguel; Ferreira, Laura Fernandes; Caldas, Mariana; Magalhães, Mariana; Figueiras, Ana; Ribeiro, Antônio J.; Veiga, Francisco

doi:10.1016/j.tifs.2019.07.048

Cited by 61 publications

(23 citation statements)

References 100 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Examples of nanoplatforms that have been proposed include liposomes [ 25 , 26 , 27 , 28 ], cyclodextrins [ 29 , 30 , 31 ], solid lipid nanoparticles [ 32 , 33 , 34 ], polymeric micelles [ 35 ], and polymeric nanoparticles [ 36 , 37 , 38 ]. However, these carriers suffer from limitations related to poor stability, low drug loading, the use of organic solvents, and high production costs [ 39 ]. In contrast, mesoporous silica nanoparticles (MSNs) exhibit several superior features in comparison to other nanocarriers such as a high drug loading capability due to their high surface area and pore volume, tunable mesopore size and pore/shape connectivity, easy surface functionalization, controllable degradability in biological environments, high in vitro and in vivo biocompatibility, and a high level of clearance and excretion [ 40 ].…”

Section: Introductionmentioning

confidence: 99%

Encapsulation and Enhanced Release of Resveratrol from Mesoporous Silica Nanoparticles for Melanoma Therapy

et al. 2021

View full text Add to dashboard Cite

Chemotherapy has limited success in the treatment of malignant melanoma due to fast development of drug resistance and the low bioavailability of chemotherapeutic drugs. Resveratrol (RES) is a natural polyphenol with recognized preventive and therapeutic anti-cancer properties. However, poor RES solubility hampers its bioactivity, thus creating a demand for suitable drug delivery systems to improve it. This work aimed to assess the potential of RES-loaded mesoporous silica nanoparticles (MSNs) for human melanoma treatment. RES was efficiently loaded (efficiency > 93%) onto spheroidal (size~60 nm) MSNs. The encapsulation promoted the amorphization of RES and enhanced the release in vitro compared to non-encapsulated RES. The RES release was pH-dependent and markedly faster at pH 5.2 (acid environment in some tumorous tissues) than at pH 7.4 in both encapsulated and bulk forms. The RES release from loaded MSNs was gradual with time, without a burst effect, and well-described by the Weibull model. In vitro cytotoxicity studies on human A375 and MNT-1 melanoma cellular cultures showed a decrease in the cell viability with increasing concentration of RES-loaded MSNs, indicating the potent action of the released RES in both cell lines. The amelanotic cell line A375 was more sensitive to RES concentration than the melanotic MNT-1 cells.

show abstract

Section: Introductionmentioning

confidence: 99%

Encapsulation and Enhanced Release of Resveratrol from Mesoporous Silica Nanoparticles for Melanoma Therapy

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Recently, various approaches have been proposed to improve RSV biological activities after systemic and topical administration; these strategies include RSV incorporation into different types of nanocarriers and synthesis of prodrugs or RSV derivatives with improved chemical–physical characteristics compared to the parent drug [ 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 ]. In particular, several studies suggest the feasibility of improving RSV effectiveness by synthesizing derivatives in which molecules that might exert a synergic effect are linked to RSV (i.e., RSV hybrids and codrugs) [ 24 , 25 ].…”

Section: Introductionmentioning

confidence: 99%

In Vitro Antioxidant and Anti-Glycation Activity of Resveratrol and Its Novel Triester with Trolox

et al. 2020

View full text Add to dashboard Cite

Resveratrol (RSV) is well known for its many beneficial activities, but its unfavorable physicochemical properties impair its effectiveness after systemic and topical administration; thus, several strategies have been investigated to improve RSV efficacy. With this aim, in this work, we synthesized a novel RSV triester with trolox, an analogue of vitamin E with strong antioxidant activity. The new RSV derivative (RSVTR) was assayed in vitro to evaluate its antioxidant and anti-glycation activity compared to RSV. RSVTR chemical stability was assessed at pH 2.0, 6.8, and 7.2 and different storage temperatures (5 °C, 22 °C, and 37 °C). An influence of pH stronger than that of temperature on RSVTR half-life values was pointed out, and RSVTR greatest stability was observed at pH 7.2 and 5 °C. RSVTR showed a lower antioxidant ability compared to RSV (determined by the oxygen radical absorbance capacity assay) while its anti-glycation activity (evaluated using the Maillard reaction) was significantly greater than that of RSV. The improved ability to inhibit the glycation process was attributed to a better interaction of RSVTR with albumin owing to its increased topological polar surface area value and H-bond acceptor number compared to RSV. Therefore, RSVTR could be regarded as a promising anti-glycation agent worthy of further investigations.

show abstract

“…Nanomedicine strategies can circumvent various disadvantages and potentiate the therapeutic benefits of repurposed antiviral molecules by increasing bioavailability, localizing the delivery to the infection sites (viral reservoir sites such as ACE 2 expressing cells, domains of viral S protein, cathepsinbinding sites), decreasing off-targeted effects, and weakening the resistance development mechanisms [56,57]. Nanocarriers can deliver a range of small molecules, biologicals (RNA interference, antibodies, proteins, antigens), peptides, and combined therapeutics as well [6,[58][59][60]. Nanocarriers also ensure the physical prevention of the biological molecules against the premature degradation in harsh biological environments, whilst evading the immune recognition and minimizing renal and/or hepatic clearance [6,61].…”

Section: Nanotechnology Direction For Sars-cov-2 Treatment and Vaccinationmentioning

confidence: 99%

Unleashing the potential of cell membrane-based nanoparticles for COVID-19 treatment and vaccination

Pereira-Silva

Chauhan

Shin

et al. 2021

Expert Opinion on Drug Delivery

Self Cite

View full text Add to dashboard Cite

Introduction : Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a particular coronavirus strain responsible for the coronavirus disease 2019 (COVID-19), accounting for more than 3.1 million deaths worldwide. Several health-related strategies have been successfully developed to contain the rapidly-spreading virus across the globe, toward reduction of both disease burden and infection rates. Particularly, attention has been focused on either the development of novel drugs and vaccines, or by adapting already-existing drugs for COVID-19 treatment, mobilizing huge efforts to block disease progression and to overcome the shortage of effective measures available at this point. Areas covered : This perspective covers the breakthrough of multifunctional biomimetic cell membrane-based nanoparticles as next-generation nanosystems for cutting-edge COVID-19 therapeutics and vaccination, specifically cell membrane-derived nanovesicles and cell membrane-coated nanoparticles, both tailorable cell membrane-based nanosystems enriched with the surface repertoire of native cell membranes, toward maximized biointerfacing, immune evasion, cell targeting and cell-mimicking properties. Expert opinion : Nano-based approaches have received widespread interest regarding enhanced antigen delivery, prolonged blood circulation half-life and controlled release of drugs. Cell membrane-based nanoparticles comprise interesting antiviral multifunctional nanoplatforms for blocking SARS-CoV-2 binding to host cells, reducing inflammation through cytokine neutralization and improving drug delivery toward COVID-19 treatment.

show abstract

Nanocarriers for resveratrol delivery: Impact on stability and solubility concerns

Cited by 61 publications

References 100 publications

Encapsulation and Enhanced Release of Resveratrol from Mesoporous Silica Nanoparticles for Melanoma Therapy

Encapsulation and Enhanced Release of Resveratrol from Mesoporous Silica Nanoparticles for Melanoma Therapy

In Vitro Antioxidant and Anti-Glycation Activity of Resveratrol and Its Novel Triester with Trolox

Unleashing the potential of cell membrane-based nanoparticles for COVID-19 treatment and vaccination

Contact Info

Product

Resources

About